Adicet Bio Shares Rise Ahead Of Prula-cel Clinical Data Update
(RTTNews) - Adicet Bio, Inc. (ACET) shares in the pre-market are active ahead of the company's planned release of Phase 1 clinical data for prulacabtagene leucel (prula-cel) in systemic lupus erythematosus (SLE), with or without lupus nephritis (LN).
The data is scheduled for September 28, 2026, and the company will host a webcast at 8:00 a.m. ET to discuss the data.
Adicet Bio is a clinical-stage biotechnology company developing allogenic gamma delta CAR-T and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies, and solid tumors.
Near-Term Milestones
The key near-term catalyst is the Phase 1 prula-cel update, which is expected to include data from 22 patients with LN and SLE, including 13 patients with at least 12 months of follow-up. Adicet has also completed the last patient visit for the planned analysis.
Beyond prula-cel, Adicet expects to initiate Phase 1 development of ADI-212, its gene-edited CAR-T candidate targeting prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer, in the fourth quarter of 2026, subject to regulatory clearance.
The company is also advancing pivotal program for prula-cel in LN and developing its in vivo CAR-T platform.
Recent Financial Results
For the second quarter ended June 30, 2026, Adicet reported a net loss of $21.36 million, or $1.99 per share, compared to $31.22 million, or $5.48 per share, in the year-ago quarter.
Cash, cash equivalents, and short-term investments in treasury securities totaled $118.19 million as of June 30, 2026. The company said the current cash runway was expected to fund operating expenses into the second half of 2027.
Stock Quote
On Friday, ACET closed trade at $9.02, up 9.07%.
In the pre-market trade, shares are up 16.08% at $10.47.
